Amend Medical Innovations is developing a next-generation device designed to close and permanently seal the left atrial appendage — addressing the critical limitations of current therapies for patients with atrial fibrillation.
For patients with atrial fibrillation, the left atrial appendage is the primary source of stroke-causing clots. Existing approaches fall short of complete, reliable protection.
Millions of patients rely on daily blood thinners. While effective, they carry ongoing bleeding risk and adherence challenges that leave many unprotected.
First-generation closure devices can leave small or large residual leaks. These stagnant areas can become new sources of embolic clots or force patients back onto medication.
Even small, hard-to-detect leaks are associated with higher rates of ischemic events. Achieving a true, durable seal remains the unmet clinical need.
The Amend device is engineered to invert and capture LAA tissue, then permanently seal the appendage with a fabric-covered surface that promotes natural endothelialization.
By eliminating residual pouches and stagnant zones, the design aims to deliver the complete occlusion that current technologies struggle to achieve consistently.
We are focused on the clinical problem that matters most: durable, leak-free exclusion of the left atrial appendage.
Leaks remain the major limitation of currently approved devices. Solving this creates the opportunity for meaningfully lower stroke risk and fewer patients returning to medical therapy.
Our approach combines mechanical inversion of the appendage with a sealing cover — aiming to leave no residual space where clots can form.
Multi-timepoint animal studies have demonstrated excellent device endothelialization, complete coverage of the appendage, and absence of chronic pathologic findings.
We are advancing through a staged clinical development program designed to generate the evidence needed for approval, reimbursement, and broad adoption.
Years of focused development have produced a strong technical, intellectual property, and preclinical data package.
Incubated and advanced since 2020 with continuous refinement of device and delivery.
Issued and pending patents covering the inversion method, grabber design, and delivery features.
Preclinical work complete. Preparing first-in-human evaluation to confirm safety and performance.
A focused group of clinicians, engineers, and advisors committed to bringing a better solution to patients and physicians.
Director of the CardioVascular Center and Department of Internal Medicine, Cardiology, and Vascular Medicine
Director of Interventional & Structural Cardiac Innovations and Cardiac Research
Helmsley Trust Professor of Medicine; Director, Cardiac Arrhythmia Service
Director of Heart Failure Hemodynamics and Circulatory Support
We welcome conversations with clinicians, strategic partners, and investors who share our commitment to improving outcomes for patients with atrial fibrillation.
Email Us